4108-88-7

Basic information

• Product Name: 1-Pyrrolidinesulfonamide(7CI,8CI,9CI)
• Synonyms: 1-Pyrrolidinesulfonamide(7CI,8CI,9CI);1-PyrrolidinesulfoaMide;1-PyrrolidinesulfonaMide;Pyrrolidine-1-sulfonic acid aMide;1-Sulphamoylpyrrolidine, 1-(Aminosulphonyl)pyrrolidine;Pyrrolidine-1-sulphonamide
• CAS NO: 4108-88-7
• Molecular Formula: C₄H₁₀N₂O₂S
• Molecular Weight: 150.2
• Product Categories: SULFONAMIDE
• Mol File: 4108-88-7.mol
• Article Data: 15

Chemical Properties

• Boiling Point: 287.488 °C at 760 mmHg
• Flash Point: 127.668 °C
• Appearance: /
• Density: 1.408 g/cm³
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 1-Pyrrolidinesulfonamide(7CI,8CI,9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Pyrrolidinesulfonamide(7CI,8CI,9CI)(4108-88-7)
• EPA Substance Registry System: 1-Pyrrolidinesulfonamide(7CI,8CI,9CI)(4108-88-7)

Safety Data

• Hazardous Substances Data: 4108-88-7(Hazardous Substances Data)

Usage

General Description

1-Pyrrolidinesulfonamide, also known as 1-Pyrrolidinesulfonamide(7CI,8CI,9CI), is a chemical compound that belongs to the class of pyrrolidines. It has the molecular formula C4H8N2O2S and a molecular weight of 152.18 g/mol. 1-Pyrrolidinesulfonamide(7CI,8CI,9CI) has various uses, including in the synthesis of pharmaceuticals, agrochemicals, and other organic compounds. It is also used as an intermediate in the production of surfactants, pigments, and dyes. Additionally, it has been studied for its potential applications in medical research, particularly in the development of new drugs and treatments. Overall, 1-Pyrrolidinesulfonamide is a versatile chemical with a range of industrial and scientific applications.

InChI:InChI=1S/C4H10N2O2S/c5-9(7,8)6-3-1-2-4-6/h1-4H2,(H2,5,7,8)

Upstream product

• 123-75-1 pyrrolidine 
• 108555-00-6 4-nitrophenyl sulfamate 
• 874124-81-9 [N-(tert-butoxycarbonyl)]-pyrrolidine-1-sulfonic acid amide 

Downstream Products

• 1211973-65-7 4-methyl-N-(pyrrolidin-1-ylsulfonyl)benzamide 
• 1211973-47-5 N-(pyrrolidin-1-ylsulfonyl)benzamide 
• 1422251-74-8 C₂₉H₃₆N₄O₆S 
• 1351565-72-4 2-[(5Z)-5-({1-[4-chloro-2-(trifluoromethyl)benzyl]-3-methyl-1H-indazol-5-yl}methylidene)-2,4-dioxo-1,3-thiazolidin-3-yl]-N-(pyrrolidin-1-ylsulfonyl)acetamide 
• 1351565-70-2 2-[(5Z)-5-({1-[4-chloro-2-(trifluoromethyl)benzyl]-1Hindazol-5-yl}methylidene)-2,4-dioxo-1,3-thiazolidin-3-yl]-N-(pyrrolidin-1-ylsulfonyl)acetamide 
• 1211973-62-4 4-cyano-N-(pyrrolidin-1-ylsulfonyl)benzamide 
• 1253286-64-4 N₁,N₁-dimethyl-N₄-(pyrrolidin-1-ylsulfonyl)terephthalamide 
• 1211973-63-5 4-methoxy-N-(pyrrolidin-1-ylsulfonyl)benzamide 
• 1211973-60-2 3-chloro-N-(pyrrolidin-1-ylsulfonyl)benzamide 
• 1211973-48-6 2-methyl-N-(pyrrolidin-1-ylsulfonyl)benzamide 
• 1211973-49-7 2-methoxy-N-(pyrrolidin-1-ylsulfonyl)benzamide 
• 1253286-65-5 4-tert-butyl-N-(pyrrolidin-1-ylsulfonyl)benzamide 
• 1211973-50-0 2-chloro-N-(pyrrolidin-1-ylsulfonyl)benzamide 
• 1211973-58-8 3-methoxy-N-(pyrrolidin-1-ylsulfonyl)benzamide 

Relevant articles and documents

7-(2-anilinopyrimidin-4-yl)-1-benzazepin-2-ones designed by a “cut and glue” strategy are dual aurora a/vegf-r kinase inhibitors

Although overexpression and hyperactivity of protein kinases are causative for a wide range of human cancers, protein kinase inhibitors currently approved as cancer drugs address only a limited number of these enzymes. To identify new chemotypes addressing alternative protein kinases, the basic structure of a known PLK1/VEGF-R2 inhibitor class was formally dissected and reassembled. The resulting 7-(2-anilinopyrimidin-4-yl)-1-benzazepin-2-ones were synthesized and proved to be dual inhibitors of Aurora A kinase and VEGF receptor kinases. Crystal structures of two representatives of the new chemotype in complex with Aurora A showed the ligand orientation in the ATP binding pocket and provided the basis for rational structural modifications. Congeners with attached sulfamide substituents retained Aurora A inhibitory activity. In vitro screening of two members of the new kinase inhibitor family against the cancer cell line panel of the National Cancer Institute (NCI) showed antiproliferative activity in the single-digit micromolar concentration range in the majority of the cell lines.

COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY

This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt and/or hydrate and/or prodrug of the compound) that modulate (e.g., agonize) the apelin receptor (also referred to herein as the APJ receptor; gene symbol APLNR). This disclosure also features compositions containing the same as well as other methods of using and making the same. The chemical entities are useful, e.g., for treating a subject (e.g., a human) having a disease, disorder, or condition in which a decrease in APJ receptor activity (e.g., repressed or impaired APJ receptor signaling; e.g., repressed or impaired apelin-APJ receptor signaling) or downregulation of endogenous apelin contributes to the pathology and/or symptoms and/or progression of the disease, disorder, or condition. Non-limiting examples of such diseases, disorders, or conditions include: (i) cardiovascular disease; (ii) metabolic disorders; (iii) diseases, disorders, and conditions associated with vascular pathology; and (iv) organ failure; (v) diseases, disorders, and conditions associated with infections (e.g., microbial infections); and (vi) diseases, disorders, or conditions that are sequela or comorbid with any of the foregoing or any disclosed herein. More particular non-limiting examples of such diseases, disorders, or conditions include pulmonary hypertension (e.g., PAH); heart failure; type II diabetes; renal failure; sepsis; and systemic hypertension.

Organic compounds and their uses

The present application describes organic compounds of Formula (II) that are useful for the treatment, prevention and/or amelioration of human diseases.